A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/167 (2006.01) A61P 9/10 (2006.01)
Patent
CA 2544632
The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.
L'invention concerne l'utilisation de composés améliorant la transcription de la synthase endothéliale d'oxyde nitrique (eNOS) aux fins de traitement de cellules souches et progénitrices dans la thérapie cellulaire de patients souffrant de cardiopathies ischémiques, telles qu'une maladie coronarienne ou une cardiomyopathie ischémique. Le traitement de telles cellules isolées de la moelle osseuse, par exemple, au moyen d'un amplificateur de la transcription de la eNOS, avant l'administration de celles-ci, permet d'améliorer l'activité fonctionnelle de celles-ci et la néovascularisation de la régénération du coeur et cardiaque.
Dimmeler Stefanie
Heeschen Christopher
Ruetten Hartmut
Zeiher Andreas
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Sanofi-Aventis Deutschland Gmbh
LandOfFree
Enos transcription enhancers for use in the cell therapy of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enos transcription enhancers for use in the cell therapy of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enos transcription enhancers for use in the cell therapy of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1534151